Merck To Pay $280 Million Dey Settlement
From UPI Business News (December 21, 2010)
German drug maker Merck KGaA is responsible for paying a $280 million settlement Dey Pharma LP reached with the U.S. government, Mylan Inc. says.
Mylan, the New Jersey pharmaceutical giant that acquired Dey in 2007, said in a release following Monday’s announcement of the settlement of the Medicare and Medicaid reimbursement lawsuit that Merck also is on the hook for all costs and expenses related to similar pending and future suits involving its subsidiary.
The U.S. Justice Department’s lawsuit began before Mylan acquired Dey.
Mylan said the settlement agreement is not an admission, finding, or evidence of fault, liability or wrongdoing by Dey.
The Justice Department alleged Dey reported false prices for Albuterol Sulfate, Albuterol MDI, Cromolyn Sodium and Ipratropium Bromide, resulting in excessive payments on millions of claims paid by Medicare and Medicaid.
Posted: December 2010